445305-91-9

Basic information

• Product Name: Cyclobutanesulfonamide (9CI)
• Synonyms: Cyclobutanesulfonamide (9CI);cyclobutanesulfonamide
• CAS NO: 445305-91-9
• Molecular Formula: C₄H₉NO₂S
• Molecular Weight: 135.18476
• Product Categories: SULFONAMIDE
• Mol File: 445305-91-9.mol
• Article Data: 22

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Cyclobutanesulfonamide (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclobutanesulfonamide (9CI)(445305-91-9)
• EPA Substance Registry System: Cyclobutanesulfonamide (9CI)(445305-91-9)

Safety Data

• Hazardous Substances Data: 445305-91-9(Hazardous Substances Data)

Upstream product

• 4399-47-7 Bromocyclobutane 
• 338453-16-0 cyclobutanesulfonyl chloride 

Downstream Products

• 1127237-77-7 5-[13-cyclohexyl-3-methoxy-10-[[[(cyclobutyl)sulfonyl]amino]carbonyl]-7H-indolo[2,1-a][2]benzazepin-6-yl]-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.